• Explore /
  • Poster
  • / AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).

AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Jia Fan

Fudan University Zhongshan Hospital, Shanghai, China

Jia Fan , Zhenggang Ren , Chiun Hsu , Yabing Guo , Tianqiang Song , Wentao Wang , Yee Chao , Yujuan Gao , Bai Li , Salvatore Ferro , Chia-Jui Yen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04948697

DOI

10.1200/JCO.2022.40.4_suppl.TPS488

Abstract #

TPS488

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jia Fan

First Author: Sophia Frentzas

First Author: Kristoffer Staal Rohrberg

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

First Author: David Hsieh